JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE
Delisted
JNCE was delisted on the 3rd of May, 2023.
115 hedge funds and large institutions have $271M invested in Jounce Therapeutics, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 44 increasing their positions, 35 reducing their positions, and 25 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
56% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 25
Holders
115
Holding in Top 10
2
Calls
$570K
Puts
$180K
Top Buyers
| 1 | +$14.9M | |
| 2 | +$10.4M | |
| 3 | +$4.35M | |
| 4 |
Goldman Sachs
New York
|
+$3.79M |
| 5 |
O
OrbiMed
New York
|
+$3.78M |
Top Sellers
| 1 | -$13M | |
| 2 | -$3.49M | |
| 3 | -$3.3M | |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$2.86M |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$2.6M |